Literature DB >> 32844178

One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes.

Kimber M Simmons1, Jay M Sosenko2, Megan Warnock3, Susan Geyer3, Heba M Ismail4, Helena Elding Larsson5, Andrea K Steck1.   

Abstract

CONTEXT: Once islet autoantibody-positive individuals are identified, predicting which individuals are at highest risk for type 1 diabetes (T1D) is important. A metabolic risk score derived from 2-hour oral glucose tolerance test (OGTT) data, the Diabetes Prevention Trial-Type 1 risk score (DPTRS), can accurately predict T1D. However, 2-hour OGTTs are time-consuming and costly.
OBJECTIVE: We aimed to determine whether a risk score derived from 1-hour OGTT data can predict T1D as accurately as the DPTRS. Secondarily, we evaluated whether a 1-hour glucose value can be used for diagnostic surveillance.
METHODS: The DPTRS was modified to derive a 1-hour OGTT risk score (DPTRS60) using fasting C-peptide, 1-hour glucose and C-peptide, age, and body mass index. Areas under receiver operating curves (ROCAUCs) were used to compare prediction accuracies of DPTRS60 with DPTRS in Diabetes Prevention Trial-Type 1 (DPT-1) (n = 654) and TrialNet Pathway to Prevention (TNPTP) (n = 4610) participants. Negative predictive values (NPV) for T1D diagnosis were derived for 1-hour glucose thresholds.
RESULTS: ROCAUCs for T1D prediction 5 years from baseline were similar between DPTRS60 and DPTRS (DPT-1: 0.805 and 0.794; TNPTP: 0.832 and 0.847, respectively). DPTRS60 predicted T1D significantly better than 2-hour glucose (P < .001 in both cohorts). A 1-hour glucose of less than 180 mg/dL had a similar NPV, positive predictive value, and specificity for T1D development before the next 6-month visit as the standard 2-hour threshold of less than 140 mg/dL (both ≥ 98.5%).
CONCLUSION: A 1-hour OGTT can predict T1D as accurately as a 2-hour OGTT with minimal risk of missing a T1D diagnosis before the next visit. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  autoantibody; diagnosis; metabolic risk; oral glucose tolerance test; prediction; type 1 diabetes

Mesh:

Substances:

Year:  2020        PMID: 32844178      PMCID: PMC7514797          DOI: 10.1210/clinem/dgaa592

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks.

Authors:  Paul Blanche; Jean-François Dartigues; Hélène Jacqmin-Gadda
Journal:  Stat Med       Date:  2013-09-12       Impact factor: 2.373

2.  Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors: 
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

Review 3.  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019.

Authors: 
Journal:  Diabetes Care       Date:  2019-01       Impact factor: 19.112

Review 4.  The development, validation, and utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS).

Authors:  Jay M Sosenko; Jay S Skyler; Jerry P Palmer
Journal:  Curr Diab Rep       Date:  2015-08       Impact factor: 4.810

5.  Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

Authors:  Jay S Skyler; Jeffrey P Krischer; Joseph Wolfsdorf; Catherine Cowie; Jerry P Palmer; Carla Greenbaum; David Cuthbertson; Lisa E Rafkin-Mervis; H Peter Chase; Ellen Leschek
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

6.  Feasibility of screening for T1D and celiac disease in a pediatric clinic setting.

Authors:  Patricia D Gesualdo; Kimberly A Bautista; Kathleen C Waugh; Liping Yu; Jill M Norris; Marian J Rewers; Judith Baxter
Journal:  Pediatr Diabetes       Date:  2015-08-06       Impact factor: 4.866

7.  Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany.

Authors:  Anette-Gabriele Ziegler; Kerstin Kick; Ezio Bonifacio; Florian Haupt; Markus Hippich; Desiree Dunstheimer; Martin Lang; Otto Laub; Katharina Warncke; Karin Lange; Robin Assfalg; Manja Jolink; Christiane Winkler; Peter Achenbach
Journal:  JAMA       Date:  2020-01-28       Impact factor: 56.272

8.  Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Authors:  Jay M Sosenko; Jerry P Palmer; Lisa Rafkin-Mervis; Jeffrey P Krischer; David Cuthbertson; Della Matheson; Jay S Skyler
Journal:  Diabetes Care       Date:  2008-07-23       Impact factor: 17.152

9.  Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.

Authors:  Jay M Sosenko; Jay S Skyler; Jeffrey Mahon; Jeffrey P Krischer; Carla J Greenbaum; Lisa E Rafkin; Craig A Beam; David C Boulware; Della Matheson; David Cuthbertson; Kevan C Herold; George Eisenbarth; Jerry P Palmer
Journal:  Diabetes Care       Date:  2014-02-18       Impact factor: 19.112

10.  Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.

Authors:  Brandon M Nathan; David Boulware; Susan Geyer; Mark A Atkinson; Peter Colman; Robin Goland; William Russell; John M Wentworth; Darrell M Wilson; Carmella Evans-Molina; Diane Wherrett; Jay S Skyler; Antoinette Moran; Jay M Sosenko
Journal:  Diabetes Care       Date:  2017-08-31       Impact factor: 19.112

View more
  6 in total

1.  Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes.

Authors:  Brandon M Nathan; Maria J Redondo; Heba Ismail; Laura Jacobsen; Emily K Sims; Jerry Palmer; Jay Skyler; Laura Bocchino; Susan Geyer; Jay M Sosenko
Journal:  Diabetes Care       Date:  2022-02-01       Impact factor: 19.112

Review 2.  Pancreatic islet reserve in type 1 diabetes.

Authors:  Anneliese J S Flatt; Carla J Greenbaum; James A M Shaw; Michael R Rickels
Journal:  Ann N Y Acad Sci       Date:  2021-02-06       Impact factor: 6.499

Review 3.  The 1-Hour Plasma Glucose: Common Link Across the Glycemic Spectrum.

Authors:  Michael Bergman
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-07       Impact factor: 5.555

4.  Continuous Glucose Monitoring Profiles in Healthy, Nondiabetic Young Children.

Authors:  Stephanie N DuBose; Lauren G Kanapka; Brenda Bradfield; Morgan Sooy; Roy W Beck; Andrea K Steck
Journal:  J Endocr Soc       Date:  2022-04-09

Review 5.  The Oral Glucose Tolerance Test: 100 Years Later.

Authors:  Ram Jagannathan; João Sérgio Neves; Brenda Dorcely; Stephanie T Chung; Kosuke Tamura; Mary Rhee; Michael Bergman
Journal:  Diabetes Metab Syndr Obes       Date:  2020-10-19       Impact factor: 3.168

6.  Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.

Authors:  Naiara G Bediaga; Connie S N Li-Wai-Suen; Michael J Haller; Stephen E Gitelman; Carmella Evans-Molina; Peter A Gottlieb; Markus Hippich; Anette-Gabriele Ziegler; Ake Lernmark; Linda A DiMeglio; Diane K Wherrett; Peter G Colman; Leonard C Harrison; John M Wentworth
Journal:  Diabetologia       Date:  2021-08-02       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.